<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085043</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0053</org_study_id>
    <secondary_id>NCI-2018-01308</secondary_id>
    <secondary_id>2015-0053</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03085043</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer</brief_title>
  <official_title>Magnetic Resonance Imaging as a Comprehensive Staging Tool for the Evaluation of High-Risk Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well magnetic resonance whole body diffusion-weighted imaging works in
      finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with
      high-risk prostate cancer. Diagnostic procedures, such as magnetic resonance whole body
      diffusion-weighted imaging (a method to show how water moves in a certain area) may help find
      bone or lymph nodes metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare accuracies of whole body magnetic resonance imaging (MRI) versus bone scan plus
      computed tomography (CT) scan in detecting bone or lymph node metastasis in high risk
      prostate cancer patients.

      OUTLINE:

      Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic
      MRI. Participants also undergo magnetic resonance whole body (WB)-diffusion-weighted imaging
      (DWI) over 20-30 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of whole body magnetic resonance imaging (MRI)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Accuracy will be estimated along with 95% confidence intervals for whole body MRI (for bone and lymph node metastasis), bone scan (for bone metastasis), and computed tomography (CT) scan (for lymph node metastasis). Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of MRI, bone scan, and CT scan</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Sensitivity will be estimated along with 95% confidence intervals for whole body MRI (for bone and lymph node metastasis), bone scan (for bone metastasis), and CT scan (for lymph node metastasis). Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of MRI, bone scan, and CT scan</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Specificity will be estimated along with 95% confidence intervals for whole body MRI (for bone and lymph node metastasis), bone scan (for bone metastasis), and CT scan (for lymph node metastasis). Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) of MRI, bone scan, and CT scan</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>PPV will be estimated along with 95% confidence intervals for whole body MRI (for bone and lymph node metastasis), bone scan (for bone metastasis), and CT scan (for lymph node metastasis). Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV) of MRI, bone scan, and CT scan</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>NPV will be estimated along with 95% confidence intervals for whole body MRI (for bone and lymph node metastasis), bone scan (for bone metastasis), and CT scan (for lymph node metastasis). Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of other types of metastases</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Scan</intervention_name>
    <description>Undergo bone scan</description>
    <arm_group_label>Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo CT of the abdomen and pelvis</description>
    <arm_group_label>Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo pelvic MRI</description>
    <arm_group_label>Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Whole Body Diffusion-Weighted Imaging</intervention_name>
    <description>Undergo magnetic resonance whole body diffusion-weighted imaging</description>
    <arm_group_label>Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)</arm_group_label>
    <other_name>WB DW MRI</other_name>
    <other_name>WB-DWI</other_name>
    <other_name>Whole Body Magnetic Resonance Imaging Using Diffusion-Weighted Images</other_name>
    <other_name>Whole-Body Diffusion-Weighted MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate carcinoma patients at high risk for metastasis with prostate-specific antigen
             (PSA) more than 20 ng/ml and/or Gleason score = 8/ &gt; 8.

          -  Ability to understand and sign informed consent.

        Exclusion Criteria:

          -  Patient is at low risk for metastasis with Gleason score at diagnosis &lt; 8.

          -  Currently receiving or history of systemic therapy with testosterone suppressing
             medication (i.e., lupron, degarelix, abiraterone, enzalutamide) or local radiation
             therapy.

          -  Contraindication to magnetic resonance imaging (MRI).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tharakeswara K Bathala</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tharakeswara K. Bathala, MBBS,MD</last_name>
    <phone>713-792-2533</phone>
    <email>TKBathala@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tharakeswara K. Bathala</last_name>
      <phone>713-792-2533</phone>
    </contact>
    <investigator>
      <last_name>Tharakeswara K. Bathala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

